Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

NZ company finds major error with cold and flu products

New Zealand company finds major formulation error with cold and flu products worth NZ$1.4 billion worldwide

AFT Pharmaceuticals has identified a major error with the formulation of over 1300 cold and flu products used around the world.

Many over the counter cold and flu products combine phenylephrine and paracetamol. The company’s groundbreaking research has revealed that when combined with paracetamol the level of phenylephrine is effectively twice what it should be.

AFT Pharmaceutical’s findings have been published today in the New England Journal of Medicine. The Journal is considered to be the most prestigious medical journal in the world. “Frankly this is a pretty big finding, with huge implications for this category of product, and it’s reflected in the fact that the New England Journal of Medicine has published what we have found,” said Dr Hartley Atkinson, Managing Director of AFT Pharmaceuticals.

“This is a very significant finding given the volume of over the counter cold and flu products that are consumed each year,” said Dr Atkinson. “The standard dose of phenylephrine in these products is 10mg. That’s all the drug regulatory authorities have allowed. But unbeknown to everyone including the regulators, when you add phenylephrine to paracetamol, the concentration of phenylephrine spikes to roughly 20mg because of the way the human body processes both drugs together. Basically this research tells us that people have inadvertently been taking the equivalent of double the recommended levels of phenylephrine.”

The use of phenylephrine together with paracetamol has increased significantly in recent years. Previously paracetamol was typically combined with pseudoephedrine. But in many countries pseudoephedrine-based products are now only available on prescription because of pseudoephedrine’s use in making the illegal drug methamphetamine.

“This is what makes these findings so important,” says Dr Atkinson. “Phenylephrine has been the ready replacement for pseudoephedrine in cold and flu remedies globally. But the international pharmaceutical companies and drug regulators haven’t known about the interaction between these two drugs. Until now.”

The side effects of an increased amount of phenylephrine may include nervousness, feelings of being unwell, and possibly increased blood pressure. People susceptible to cardiovascular effects may require extra care. But Dr Atkinson said that addressing the consequences of AFT Pharmaceutical’s findings are now in the hands of others. “We immediately informed Medsafe (NZ) and the Therapeutic Goods Administration (Australia) of our findings. It is now up to the regulators to use the information as they see fit. We have also met with the United States Food and Drug Administration in January this year to fully inform them of our findings.”

AFT Pharmaceutical’s discovery was the result of its standard analgesics research programme. The company has now reformulated its cold and flu medication and invented a new formulation that delivers the intended 10mg of phenylephrine to consumers when given in combination with paracetamol. This new product is ready to be filed within the next month for regulatory evaluation in New Zealand and Australia.

These unexpected findings have thrown the international spotlight on AFT Pharmaceuticals. Dr Atkinson says the business has come a long way since it started in a room off his home garage in the late 1990s. “We’ve put a lot of time and effort into researching new products. It’s what drives us as a company and it’s paying off.” He says that this discovery, together with several other innovative new products in the pipeline, means that the future of AFT Pharmaceuticals is extremely bright.

Background to AFT

AFT Pharmaceuticals is a privately-owned New Zealand pharmaceutical company based in Auckland and Sydney. Beginning with a humble $50,000 start-up in Dr Hartley Atkinson’s home garage in 1997, AFT is now an originator of ground-breaking medicine with turnover over NZ$66 million. AFT Pharmaceuticals has over 60 products listed on New Zealand’s Pharmaceutical Schedule and sells medicines in most public and private hospitals across New Zealand. The company has recently opened offices in Kuala Lumpur and Singapore.

END

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Gita Hits NZ: 'It Was Literally Like A Wall Of Water'

"We were looking at the river at 80 cubic metres at about 4pm thinking it was amazing that we'd dodged the bullet ... an hour and a half later it was 600 cubic metres, and it just kept going up to 900 from there." More>>

ALSO:

America's Cup: Another Day, Another Cup Village Plan

A fourth option modelling what an America's Cup Village in Auckland might look like has arrived today as a planning deadline nears with no agreement in sight.More>>

Closing Or Selling Regionals: Fairfax Starts NZ Endgame

Fairfax Media Group will close or sell 35 percent of its New Zealand print titles as the Australian group pursues a digital strategy for the kiwi unit, now rebranded Stuff. More>>

Fletcher Building: Norris Steps Down As Chair After New $486M Loss Provision

Ralph Norris will step down as chairman of Fletcher Building after the company took a further $486 million provision for project losses at its Building + Interiors unit and said 14 of the unit's 73 projects, worth $2.3 billion, are loss-making or 'on watch'. More>>

ALSO:

WWF: Concerns With Suggestion To “Scrap” Fishing Monitoring

“Our Pacific neighbours, like Fiji and the Solomon Islands, are making this work with far less economic resources than New Zealand. There’s no reason the government can’t get this done by October.” More>>

ALSO:

Stink one!: Stink Bug Invasion Could Cost NZ Billions

An invasion of the brown marmorated stink bug - the pest discovered recently in three Japanese car shipments - would devastate New Zealand's fruit, vegetable and wine industries, destroying more than $4 billion of export value and costing thousands ... More>>